Obermeyer Wood Investment Counsel Lllp raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 32.0% during the third quarter, Holdings Channel reports. The firm owned 19,819 shares of the biopharmaceutical company’s stock after purchasing an additional 4,805 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Bristol-Myers Squibb were worth $1,263,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tradewinds Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares in the last quarter. Atlantic Trust LLC acquired a new position in Bristol-Myers Squibb in the 2nd quarter worth $111,000. American National Bank increased its position in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares during the last quarter. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Finally, BDO Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $123,000. Institutional investors own 69.67% of the company’s stock.

In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

Several research firms have recently weighed in on BMY. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 26th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a research report on Friday, December 22nd. Jefferies Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective for the company. in a research report on Monday, October 16th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $65.05.

Shares of Bristol-Myers Squibb Co (BMY) opened at $61.91 on Tuesday. The firm has a market cap of $101,330.00, a P/E ratio of 24.37, a PEG ratio of 2.22 and a beta of 1.18. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 earnings per share. research analysts anticipate that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a $0.40 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.58%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.

ILLEGAL ACTIVITY WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-shares-bought-by-obermeyer-wood-investment-counsel-lllp/1799300.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.